These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31237861)

  • 1. Response to sapropterin hydrochloride (Kuvan®) in children with phenylketonuria (PKU): a clinical trial.
    Eshraghi P; Noroozi Asl S; Bagheri S; Chalak V
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):885-888. PubMed ID: 31237861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria.
    Vernon HJ; Koerner CB; Johnson MR; Bergner A; Hamosh A
    Mol Genet Metab; 2010 Jul; 100(3):229-33. PubMed ID: 20418136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial.
    Muntau AC; Burlina A; Eyskens F; Freisinger P; Leuzzi V; Sivri HS; Gramer G; Pazdírková R; Cleary M; Lotz-Havla AS; Lane P; Alvarez I; Rutsch F
    Orphanet J Rare Dis; 2021 Aug; 16(1):341. PubMed ID: 34344399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.
    Sanford M; Keating GM
    Drugs; 2009; 69(4):461-76. PubMed ID: 19323589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial.
    Muntau AC; Burlina A; Eyskens F; Freisinger P; De Laet C; Leuzzi V; Rutsch F; Sivri HS; Vijay S; Bal MO; Gramer G; Pazdírková R; Cleary M; Lotz-Havla AS; Munafo A; Mould DR; Moreau-Stucker F; Rogoff D
    Orphanet J Rare Dis; 2017 Mar; 12(1):47. PubMed ID: 28274234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving patient selection and clinical benefit criteria for sapropterin dihydrochloride (Kuvan®) treatment of PKU patients.
    Gordon P; Thomas JA; Suter R; Jurecki E
    Mol Genet Metab; 2012 Apr; 105(4):672-6. PubMed ID: 22310224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.
    Burton BK; Nowacka M; Hennermann JB; Lipson M; Grange DK; Chakrapani A; Trefz F; Dorenbaum A; Imperiale M; Kim SS; Fernhoff PM
    Mol Genet Metab; 2011 Aug; 103(4):315-22. PubMed ID: 21646032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study.
    Keil S; Anjema K; van Spronsen FJ; Lambruschini N; Burlina A; Bélanger-Quintana A; Couce ML; Feillet F; Cerone R; Lotz-Havla AS; Muntau AC; Bosch AM; Meli CA; Billette de Villemeur T; Kern I; Riva E; Giovannini M; Damaj L; Leuzzi V; Blau N
    Pediatrics; 2013 Jun; 131(6):e1881-8. PubMed ID: 23690520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study.
    Burton BK; Grange DK; Milanowski A; Vockley G; Feillet F; Crombez EA; Abadie V; Harding CO; Cederbaum S; Dobbelaere D; Smith A; Dorenbaum A
    J Inherit Metab Dis; 2007 Oct; 30(5):700-7. PubMed ID: 17846916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria.
    Blau N; Bélanger-Quintana A; Demirkol M; Feillet F; Giovannini M; MacDonald A; Trefz FK; van Spronsen FJ
    Mol Genet Metab; 2009 Apr; 96(4):158-63. PubMed ID: 19208488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria.
    Elsas LJ; Greto J; Wierenga A
    Mol Genet Metab; 2011 Apr; 102(4):407-12. PubMed ID: 21216643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study.
    Bratkovic D; Margvelashvili L; Tchan MC; Nisbet J; Smith N
    Metabolism; 2022 Mar; 128():155116. PubMed ID: 34973284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved metabolic control in tetrahydrobiopterin (BH4), responsive phenylketonuria with sapropterin administered in two divided doses vs. a single daily dose.
    Kör D; Yılmaz BŞ; Bulut FD; Ceylaner S; Mungan NÖ
    J Pediatr Endocrinol Metab; 2017 Jul; 30(7):713-718. PubMed ID: 28593914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study.
    Trefz FK; Burton BK; Longo N; Casanova MM; Gruskin DJ; Dorenbaum A; Kakkis ED; Crombez EA; Grange DK; Harmatz P; Lipson MH; Milanowski A; Randolph LM; Vockley J; Whitley CB; Wolff JA; Bebchuk J; Christ-Schmidt H; Hennermann JB;
    J Pediatr; 2009 May; 154(5):700-7. PubMed ID: 19261295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Open, non-comparative phase III clinical study to evaluate the efficacy and safety of sapropterin in patients with phenylketonuria and hyperphenylalaninemia].
    Bushueva TV; Kuzenkova LM; Borovik TÉ; Nazarenko LP; Seitova GN; Filimonova MN; Pichkur NA; Samonenko NV; Shkurko TA; Akhmadeeva ÉN; Mardanova AK; Garifullina ÉR; Kovtun OP; Bazhenova IuL; Alimova IL; Kostiakova EA; Minaĭcheva LI; Saliukova OA; Sivokha VM; Rozenson OL
    Vestn Ross Akad Med Nauk; 2014; (7-8):69-77. PubMed ID: 25563006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sapropterin dihydrochloride for phenylketonuria.
    Somaraju UR; Merrin M
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD008005. PubMed ID: 25812600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to tetrahydrobiopterin therapy in patients with phenylketonuria.
    Rohr F; Wessel A; Brown M; Charette K; Levy HL
    Mol Genet Metab; 2015 Jan; 114(1):25-8. PubMed ID: 25467057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for the use of sapropterin in phenylketonuria.
    Cunningham A; Bausell H; Brown M; Chapman M; DeFouw K; Ernst S; McClure J; McCune H; O'Steen D; Pender A; Skrabal J; Wessel A; Jurecki E; Shediac R; Prasad S; Gillis J; Cederbaum S
    Mol Genet Metab; 2012 Jul; 106(3):269-76. PubMed ID: 22575621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term preservation of intellectual functioning in sapropterin-treated infants and young children with phenylketonuria: A seven-year analysis.
    Waisbren S; Burton BK; Feigenbaum A; Konczal LL; Lilienstein J; McCandless SE; Rowell R; Sanchez-Valle A; Whitehall KB; Longo N
    Mol Genet Metab; 2021 Feb; 132(2):119-127. PubMed ID: 33485801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria.
    Muntau AC; Adams DJ; Bélanger-Quintana A; Bushueva TV; Cerone R; Chien YH; Chiesa A; Coşkun T; de Las Heras J; Feillet F; Katz R; Lagler F; Piazzon F; Rohr F; van Spronsen FJ; Vargas P; Wilcox G; Bhattacharya K
    Mol Genet Metab; 2019 May; 127(1):1-11. PubMed ID: 31103398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.